The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?
Pembrolizumab plus weekly paclitaxel, with investigator-choice bevacizumab, achieved statistically significant PFS and OS improvements, addressing a high unmet need in platinum-resistant ovarian ...
Add Yahoo as a preferred source to see more of our stories on Google. Platinum-resistant ovarian cancer (PROC) remains one of the most treatment-refractory malignancies, with a median overall survival ...
LOS ANGELES -- Patients with metastatic melanoma have faced grim prospects: the American cancer society says the five-year survival rate is only 15 percent. That started changing when the FDA approved ...
KEYTRUDA monotherapy now approved as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without concomitant cisplatin then as monotherapy Based on results of ...
Keytruda is not chemotherapy. It’s a type of treatment called immunotherapy. It works with the body’s immune system, helping T cells fight cancer cells. With immunotherapy, the body’s immune system ...
Overview: Keytruda Qlex is a medicine that is used to treat many types of cancer. This medicine is given to you as an injection under your skin by a health care provider. This medicine can cause side ...
Merck’s MRK primary strength lies in oncology, propelled by its blockbuster PD-L1 inhibitor, Keytruda, which fuels robust growth across various cancer indications worldwide. The drug alone accounts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results